Anthera Pharmaceuticals Stock Gross Profit
Anthera Pharmaceuticals fundamentals help investors to digest information that contributes to Anthera Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Anthera Pink Sheet. The fundamental analysis module provides a way to measure Anthera Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Anthera Pharmaceuticals pink sheet.
Anthera |
Anthera Pharmaceuticals Company Gross Profit Analysis
Anthera Pharmaceuticals' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current Anthera Pharmaceuticals Gross Profit | (28.49 M) |
Most of Anthera Pharmaceuticals' fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Anthera Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
CompetitionAccording to the company disclosure, Anthera Pharmaceuticals reported (28.49 Million) of gross profit. This is 101.27% lower than that of the Biotechnology sector and 103.0% lower than that of the Health Care industry. The gross profit for all United States stocks is 100.1% higher than that of the company.
Anthera Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Anthera Pharmaceuticals' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Anthera Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Anthera Pharmaceuticals by comparing valuation metrics of similar companies.Anthera Pharmaceuticals is currently under evaluation in gross profit category among its peers.
Anthera Fundamentals
Return On Equity | -5.69 | ||||
Return On Asset | -1.42 | ||||
Current Valuation | (7.47 M) | ||||
Shares Outstanding | 26.18 M | ||||
Number Of Shares Shorted | 2.02 M | ||||
Price To Earning | (0.20) X | ||||
Price To Book | 0.11 X | ||||
Gross Profit | (28.49 M) | ||||
EBITDA | (26.59 M) | ||||
Net Income | (26.87 M) | ||||
Cash And Equivalents | 8.09 M | ||||
Cash Per Share | 0.31 X | ||||
Debt To Equity | 1.61 % | ||||
Current Ratio | 3.30 X | ||||
Book Value Per Share | 0.21 X | ||||
Cash Flow From Operations | (36.9 M) | ||||
Short Ratio | 2.09 X | ||||
Earnings Per Share | (1.76) X | ||||
Price To Earnings To Growth | (0.05) X | ||||
Target Price | 3.0 | ||||
Number Of Employees | 21 | ||||
Beta | -108.04 | ||||
Market Capitalization | 617.83 K | ||||
Total Asset | 3.67 M | ||||
Retained Earnings | (436.8 M) | ||||
Working Capital | 39.39 M | ||||
Current Asset | 47.86 M | ||||
Current Liabilities | 8.47 M | ||||
Net Asset | 3.67 M |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Anthera Pink Sheet
If you are still planning to invest in Anthera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Anthera Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |